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Objectives: The quality of antibiotic consumption in the community can be assessed using 12 drug-specific qual-
ity indicators (DSQIs) developed by the European Surveillance of Antimicrobial Consumption (ESAC) project. We
compared quality in 2009 and 2017 in the EU/European Economic Area (EEA) and evaluated the impact of using
different DDD values (ATC/DDD indices 2011 and 2019) for the 2009 quality assessment using these DSQIs and a
joint scientific opinion (JSO) indicator.
Methods: We calculated the 12 DSQIs and the JSO indicator for 2017 and for 2009 for EU/EEA countries able to
deliver values. For each of the indicators we grouped the 2017 and 2009 indicator values into four quartiles. To
evaluate changes in quality between 2009 and 2017, we used the quartile distribution of the 2009 indicator val-
ues in 30 EU/EEA countries as benchmarks. In addition, we compared the quality assessment for 2009 using the
ATC/DDD indices 2011 and 2019.
Results: In 2017, a difference in the quality of antibiotic consumption in the community between northern and
southern EU/EEA countries remained, but also several eastern EU/EEA countries shifted towards lower quality.
Quality of antibiotic consumption decreased between 2009 and 2017 in particular indicator values for penicillin,
quinolone, relative b-lactam and broad- versus narrow-spectrum antibiotic consumption, and seasonal vari-
ation. Using different ATC/DDD indices did not substantially change countries’ ranking based on their DSQI
values.
Conclusions: The quality of antibiotic consumption in the community as measured by the DSQIs further
decreased between 2009 and 2017, especially in Southern and Eastern European countries. A continuous effort
to improve antibiotic consumption is essential to reduce antibiotic consumption in general and the use of broad-
spectrum antibiotics in particular.
Introduction
Quality assessment and improvement in healthcare is a major
issue in many countries.1,2 Information on quality of healthcare is
being demanded by policy makers, healthcare professionals and
the general public.3 Prescribing of medicines also has a major influ-
ence on well-being and accounts for a substantial part of health-
care expenditure.4 If we want to improve the consumption of
antibiotics, we have to be able to measure the quality of antibiotic
consumption in Europe. Benchmarking by comparisons between
countries has proved to be an important stimulus to quality
improvement, in general, but also for antibiotic consumption in
particular.5 In 2007, the European Surveillance of Antimicrobial
Consumption (ESAC) project published a set of 12 drug-specific
quality indicators (DSQIs) for antibiotic consumption in the
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community (i.e. primary care sector) and calculated the indicator
values for 2004.6 It was concluded that these indicators could be
used to describe antibiotic consumption in the community and to
assess the quality of national antibiotic prescribing patterns in
Europe. In 2011, a quality appraisal of antibiotic consumption in
Europe was published to evaluate the quality of antibiotic con-
sumption in the community in 2009 and to evaluate changes in
quality between 2004 and 2009.7
In 2019, the DDDs of several substances were updated by
WHO.8,9 In particular, the DDD for amoxicillin (J01CA04) and
amoxicillin/clavulanic acid (J01CR02) changed for oral administra-
tion from 1 g to 1.5 g to better approximate the dose consumed in
daily practice.8,9 Retrospectively, this change could be applied to
previous quality assessments and would cause different values for
several indicators. Therefore, we chose to update the quality as-
sessment for 2009 and assess the impact of using the ATC/DDD
index 2019.10
In addition, on request of the European Commission, ECDC, the
European Food Safety Authority (EFSA) and EMA published a Joint
Scientific Opinion (JSO) on a list of outcome indicators with regard
to surveillance of antimicrobial resistance and antimicrobial con-
sumption in humans and food-producing animals to monitor the
EU/European Economic Area (EEA) country activities on prudent
use of antimicrobials.11 In parallel with the respective ESAC quality
indicator, the JSO proposes an indicator using a modified ratio of
consumption of broad-spectrum antibiotics fJ01[CR!DC!DD!
(F-FA01)!MA]g to the consumption of narrow-spectrum antibiot-
ics [J01(CA!CE!CF!DB!FA01)]. In this article, we will also pre-
sent results for this ECDC/EFSA/EMA JSO indicator. However, the
primary objective of this article, which is one of a series of
articles,9,12–19 is to present a detailed quality assessment of anti-
biotic consumption in the community in EU/EEA countries in 2017
and an assessment of changes in quality of this consumption be-
tween 2009 and 2017.
Methods
The methods for collecting data on consumption of systemic antibiotics are
described in the introductory article of this series.9 Antibiotic consumption
in the community was expressed in DDD per 1000 inhabitants per day using
the ATC/DDD index 2019.10 The quality of antibiotic consumption in the
community in 2017 was assessed for each country by calculating the indi-
cator values for each of the 12 DSQIs defined by the ESAC project and for
the ECDC/EFSA/EMA JSO indicator (Table 1) using data on antibiotic con-
sumption in 2017 available from the European Surveillance of Antimicrobial
Consumption Network (ESAC-Net) database and grouping these values into
quartiles.6,11 Next, for the same indicators, the 2009 indicator values were
grouped into four quartiles according to the quartile distribution of the 2009
indicator values using the 2019 DDD values.
Indicator values within the first quartile [i.e. values percentile 25
(p25)] suggest better quality than indicator values within the second quar-
tile (i.e. p25 <valuesp50), which suggest better quality than indicator val-
ues within the third quartile (i.e. p50 <values p75), which suggest better
quality than indicator values within the fourth quartile (i.e. values >p75) for
that indicator.6 Countries were ranked firstly according to the number of in-
dicator values within the fourth quartile, secondly according to the number
of indicator values within the third quartile, and thirdly according to the
number of indicator values within the second quartile, taking into account
the total number of available indicator values. The ECDC/EFSA/EMA JSO indi-
cator was not included in this ranking.
We compared the quality assessment for 2009 using the ATC/DDD indi-
ces 2011 and 2019.10,20 To evaluate changes in quality between 2009 and
2017, we used the quartile distribution of the 2009 indicator values as
benchmarks for the 2017 values. Only countries able to deliver data for
both years were included in this comparison.
Results
Figure 1 shows the 2017 indicator values for the 28 EU/EEA coun-
tries that reported 2017 antibiotic consumption data (i.e. all
Table 1. Quality indicators for outpatient antibiotic consumption in the
community
No. Label Description
1 J01 Consumption of antibacterials for systemic use
(J01) expressed in DDD per 1000 inhabitants
per day
2 J01C Consumption of penicillins (J01C) expressed in
DDD per 1000 inhabitants per day
3 J01D Consumption of cephalosporins (J01D)
expressed in DDD per 1000 inhabitants per
day
4 J01F Consumption of macrolides, lincosamides and
streptogramins (J01F) expressed in DDD per
1000 inhabitants per day
5 J01M Consumption of quinolones (J01M) expressed
in DDD per 1000 inhabitants per day
6 J01CE% Consumption of b-lactamase-sensitive penicil-
lins (J01CE) expressed as percentagea
7 J01CR% Consumption of combination of penicillins,
including b-lactamase inhibitor (J01CR)
expressed as percentagea
8 J01DD!DE% Consumption of third- and fourth-generation
cephalosporins [J01(DD!DE)] expressed as
percentagea
9 J01MA% Consumption of fluoroquinolones (J01MA)
expressed as percentagea
10 J01_B/N Ratio of the consumption of broad-spectrum
antibiotics fJ01[CR!DC!DD!(F-FA01)]g to
the consumption of narrow-spectrum antibi-
otics [J01(CE!DB!FA01)]
11 J01_SV Seasonal variation of the total antibiotic con-
sumption (J01)b
12 J01M_SV Seasonal variation of quinolone consumption
(J01M)b
13 J01_B/N_JSO Ratio of the consumption of broad-spectrum
antibiotics fJ01[CR!DC!DD!(F-
FA01)!MA]g over narrow-spectrum antibiot-
ics [J01(CA!CE!CF!DB!FA01)]
aPercentage of the total consumption of antibacterials for systemic use
(J01) expressed in DDD per 1000 inhabitants per day.
bOverconsumption in the winter quarters (October–December and
January–March) compared with the summer quarters (July–September
and April–June) of a 1 year period starting in July and ending the next
calendar year in June, expressed as percentage: [DDD (winter quarters)/
DDD (summer quarters)#1]%100.

































































Italy 19.02 8.79 1.94 3.75 2.68 0.00 35.40 8.85 14.01 208.41 37.01 31.26 7.11 
Spain 25.01 14.23 2.27 3.07 2.82 0.38 31.40 2.10 11.23 53.50 
  
2.43 
Greece 32.15 10.76 7.70 6.98 2.60 0.58 18.90 0.56 8.08 107.61 
  
4.96 
Cyprus 28.88 9.33 5.81 2.89 6.21 0.23 25.01 3.57 21.49 38.07 
  
8.85 
Romania 24.50 11.22 4.95 2.89 3.25 2.58 26.44 5.19 13.23 15.73 
  
3.45 
Bulgaria 18.94 5.38 4.11 3.82 2.86 0.69 12.46 4.69 15.10 46.34 
  
4.20 
Malta 19.79 7.34 3.12 4.46 2.18 0.70 34.04 2.93 11.02 61.25 
  
23.36 
Hungary 13.43 4.51 2.10 2.80 2.40 0.97 26.98 2.28 17.89 62.28 51.31 46.67 12.28 
Luxembourg 20.93 6.79 2.36 5.50 2.77 0.08 17.44 1.67 13.24 38.89 36.33 27.15 4.11 
Belgium 21.14 9.74 1.17 3.41 2.17 0.08 22.43 0.01 10.27 123.93 32.62 24.32 2.26 
France 22.97 13.00 1.60 3.04 1.37 0.73 19.65 5.37 5.96 37.97 
  
1.22 
Poland 23.79 6.63 3.99 4.46 1.49 1.29 11.96 0.07 6.21 20.12 
  
3.11 
Austria 11.92 5.12 1.51 2.81 1.23 6.27 29.74 2.01 10.32 6.90 59.15 48.03 4.56 
Portugal 16.37 8.67 1.64 2.44 1.26 0.08 37.16 1.50 7.67 39.19 27.62 15.81 3.96 
Germany 12.34 3.57 2.81 2.14 1.11 5.61 3.35 1.99 8.96 6.14 35.39 27.57 1.91 
Ireland 19.35 9.54 1.08 4.19 0.81 6.01 19.90 0.15 4.17 4.65 20.38 11.54 1.46 
Croatia 16.83 7.82 2.47 2.75 1.50 3.02 31.73 1.94 8.92 10.10 33.15 13.85 3.89 
Latvia 12.05 4.66 0.66 1.97 1.03 0.66 12.88 0.61 8.37 14.79 37.20 7.84 1.52 
Denmark 14.33 9.52 0.03 1.62 0.44 26.61 5.51 0.04 3.08 0.61 10.56 5.11 0.32 
Slovenia 10.74 6.87 0.37 1.68 1.11 14.62 26.88 0.52 10.30 3.04 29.86 8.97 1.49 
United Kingdom 17.06 6.37 0.24 2.90 0.45 5.02 4.09 0.06 2.65 1.74 11.07 4.54 0.53 
Iceland 18.84 9.34 0.61 1.61 0.81 9.99 16.16 0.03 4.30 1.67 13.66 1.69 0.74 
Lithuania 13.56 6.73 1.29 2.07 0.87 1.14 12.57 0.12 6.11 11.09 
  
1.06 
Finland 13.59 4.40 1.94 0.75 0.67 8.24 5.36 0.02 4.93 0.50 12.73 3.22 0.39 
Estonia 9.94 3.47 1.18 2.26 0.79 1.67 17.13 0.03 7.90 14.70 30.56 9.06 2.97 
Netherlands 8.94 2.92 0.03 1.38 0.73 2.45 10.59 0.05 8.19 8.60 
  
1.50 
Norway 14.37 5.61 0.06 1.01 0.35 20.89 0.09 0.04 2.46 0.16 
  
0.15 
Sweden 11.26 5.87 0.08 0.54 0.63 28.02 1.78 0.02 5.59 0.20 
  
0.22 
 2.92 0.03 0.54 0.35 28.02 0.09 0.01 2.46 0.16 10.56 1.69 0.15 
 5.32 0.65 1.90 0.80 6.08 11.62 0.04 5.87 4.25 18.70 7.16 1.18 
 6.83 1.62 2.80 1.24 1.48 18.17 0.59 8.28 14.74 31.59 12.70 2.35 





p100 32.15 14.23 7.70 6.98 6.21 0.00 37.16 8.85 21.49 208.41 59.15 48.03 23.36 
= values within the first quartile (i.e. p0 ≤ values ≤ p25) 
= values within the second quartile (i.e. p25 > values ≤ p50) 
= values within the third quartile (i.e. p50 > values ≤ p75) 
= values within the fourth quartile (i.e. p75 > values ≤ p100). 
Figure 1. Quality indicators for outpatient antibiotic consumption in the community, 2017 (ATC/DDD index 2019), 28 EU/EEA countries grouped into
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EU/EEA countries except Czechia and Slovakia), grouped into four
quartiles and ranked according to quality. Based on this ranking,
several Northern European countries (Finland, Iceland, Lithuania,
the Netherlands, Norway, Sweden and the United Kingdom)
showed a better quality of antibiotic consumption in the commu-
nity than Southern European countries [Cyprus (total care data),
Greece, Italy, Malta and Spain] and several Eastern European
countries [Bulgaria, Hungary and Romania (total care data)].
Compared with the previous quality assessment in 2011, several
Eastern European countries ranked lower in quality in 2017 com-
pared with 2009.
Figure 2 shows the 2009 indicator values for the 30 EU/EEA
countries that reported 2009 antibiotic consumption data,
grouped into quartiles, and ranked according to quality. By using
the ATC/DDD index 2019 instead of the ATC/DDD index 2011,20
Lithuania ranked substantially higher in quality (i.e. their ranking
changed by four or more positions) than other countries, while for
Denmark the opposite was observed.
As shown in Figure 3, quality of antibiotic consumption in the
community declined between 2009 and 2017. There were 19
more indicator values within the fourth quartile and six more indi-
cator values within the first quartile in 2017 compared with 2009;
this was at the expense of 16 fewer indicator values within the se-
cond quartile and 9 fewer indicator values within the third quartile.
The most substantial shifts towards lower quality were
observed for the following quality indicators: penicillin consump-
tion in DDD per 1000 inhabitants per day (J01C_DID), quinolone
consumption in DDD per 1000 inhabitants per day (J01M_DID), the
proportional consumption of b-lactamase-sensitive penicillins
(J01CE_%), the proportional consumption of combinations of
penicillins, including b-lactamase inhibitors (J01CR_%), the ratio of
broad- to narrow-spectrum antibiotics (J01_B/N), the seasonal
variation of total antibiotic consumption (J01_SV) and the season-
al variation of quinolone consumption (J01M_SV%).
For three quality indicators, i.e. consumption of antibacterials
for systemic use in DDD per 1000 inhabitants per day (J01_DID),
quinolone consumption in DDD per 1000 inhabitants per day
(J01M_DID) and consumption of fluoroquinolones (J01MA)
expressed as percentage (J01MA_%), shifts towards better quality
were observed.
The quality indicator J01M_DID showed the highest degree of
polarization (20 indicator values in the first and last quartile versus
8 indicator values in the second and third quartiles).
Discussion
In 2017, there still was an important North–South divide when
considering the quality of antibiotic consumption. Several Eastern
European countries [Bulgaria, Hungary and Romania (total care
data; coverage in 2009 limited to 30%–40%)] ranked lower in qual-
ity in 2017 than 2009.
The interpretation of the 2017 values using the 2009 quartile
distribution suggests that total antibiotic consumption (J01_DID)
further improved (10 of the 28 values in the first quartile), which
was caused by a shift of some countries from the second quartile
to the first quartile. There was no shift from the countries in lower
quality quartiles (third and fourth quartile). This suggests that the
countries with higher quality further improved between 2009 and
2017 whereas the countries with lower quality remained low in
quality. This was also visible in the indicator considering quinolone
consumption in DDD per 1000 inhabitants per day (J01M_DID).
Countries with better quality in 2009 seemed to reduce their
quinolone consumption whereas countries with lower quality in
2009 seemed to increase their quinolone consumption or did not
substantially reduce it.
The WHO continuously reviews its ATC/DDD methodology so
the DDDs better approximate the daily doses consumed in daily
practice. Changes in DDDs are to be kept at a minimum and
avoided as far as possible, as too many changes are disadvanta-
geous for long-term studies on drug utilization.20 There have not
been many changes in the DDDs for antibiotics, but the 2019 ver-
sion of the ATC/DDD index introduced large and important changes
for several substances. Most importantly, the DDD for amoxicillin
(J01CA04) and amoxicillin/clavulanic acid (J01CR02) changed
from 1 g to 1.5 g for oral use.8 In contrast to the results of the study
by Charra et al.,21 this change did not dramatically influence rank-
ing or alter conclusions on the quality of antibiotic consumption
compared with the assessment with previous DDD values (ATC/
DDD index 2011). The largest shifts in ranking were observed for
Lithuania (higher quality) and Denmark (lower quality). However,
interpretation of ranking should be done with caution because
these indicators are not independent. Therefore, we strongly
advise that each country critically appraises its quality indicator
values. In particular, country rankings are influenced by shifts in
total antibiotic consumption and in penicillin consumption in DDD
per 1000 inhabitants per day. For example, in Denmark, consump-
tion of extended-spectrum penicillins and combinations with a
b-lactamase inhibitor (amoxicillin and amoxicillin/clavulanic acid)
is limited compared with the other EU/EEA countries, which is not
necessarily a sign of lower quality of antibiotic consumption in the
country. Countries with high consumption of extended-spectrum
penicillins and combinations with a b-lactamase inhibitor benefit
the most from the 2019 alteration in DDDs, but the proportional
consumption of these two substances could also be considered as
a tool for quality assessment.22
For this reason, the ECDC, EFSA and EMA JSO proposed an indi-
cator using a modified ratio of consumption of combinations of
penicillins (J01CR; including the combination of amoxicillin/
clavulanic acid), broad-spectrum cephalosporins (J01DC and
J01DD), broad-spectrum macrolides (J01F, excluding J01FA01)
and fluoroquinolones (J01M) to the consumption of narrow-spec-
trum penicillins (J01CE), extended-spectrum penicillins (J01CA,
including amoxicillin), penicillinase-resistant penicillins (J01CF),
narrow-spectrum cephalosporins (J01DB) and narrow-spectrum
macrolides (J01FA01). Based on this indicator, Denmark ranked in
the first quartile. Although the indicator was not validated by a
consensus procedure, we invite countries to also consider their
position for this indicator. For example Estonia, which has all indi-
cator values within the first and second quartile when considering
the 12 ESAC DSQIs, ranked in the third quartile considering the
ECDC/EFSA/EMA JSO indicator. The authors already noted that this
indicator predominantly reflects antimicrobial consumption in the
community and should not stand alone, but be used in combin-
ation with other indicators, e.g. hospital antimicrobial consumption
indicators.11
In addition to this, we again emphasize the need for consump-
tion data that are related to clinical information to assess the
quality of antibiotic consumption.7 The ESAC project had also

































































Italy 23.73 10.25 2.77 5.33 3.61 0.01 27.62 8.66 14.56 80.99 27.77 20.05 4.63 
Luxembourg 23.75 9.06 4.33 3.87 2.80 0.40 23.66 0.05 11.80 27.91 41.84 25.70 4.24 
Cyprus 29.16 10.76 6.45 3.98 4.10 0.40 23.16 1.98 14.07 22.40 
  
4.45 
France 24.40 10.91 2.92 4.15 2.00 0.61 17.74 7.77 7.91 35.86 
  
1.95 
Spain 15.67 8.31 1.56 1.90 2.42 0.57 32.38 3.47 15.12 43.73 26.26 17.97 3.24 
Greece 34.60 8.87 8.67 11.56 2.60 2.09 10.24 0.85 7.52 29.58 34.61 3.98 4.86 
Belgium 22.16 10.16 1.82 2.94 2.61 0.45 26.61 0.00 11.77 36.19 32.66 18.89 2.94 
Slovakia 21.26 7.05 4.12 6.09 2.03 8.68 17.20 2.52 9.54 6.56 35.32 11.02 4.31 
Malta 18.60 6.10 5.50 3.89 1.65 0.15 28.24 0.97 8.88 126.74   17.42 
Poland 20.08 7.17 2.89 3.88 1.25 0.74 16.37 0.00 6.20 31.12 
  
2.75 
Portugal 19.13 8.19 1.96 3.83 3.04 0.09 31.37 1.98 15.90 18.32 27.62 8.02 5.11 
Hungary 13.86 4.94 1.98 3.00 1.79 4.85 22.19 2.78 12.72 10.87 56.78 25.82 5.06 
Austria 13.63 4.79 1.80 3.93 1.33 7.28 22.05 5.79 9.73 6.27 37.73 17.51 4.57 
Germany 13.78 3.16 2.39 2.51 1.48 6.19 1.58 3.70 10.73 3.92 45.65 32.40 1.89 
Romaniaa 9.65 3.77 2.47 1.84 1.25 1.64 24.92 1.02 12.96 6.10 
  
3.28 
Croatia 19.39 7.20 3.91 3.43 1.41 5.77 18.40 4.45 7.25 3.87 21.55 –3.61 2.20 
Bulgaria 15.91 5.76 2.30 3.16 1.97 2.28 11.25 1.04 12.39 5.40 
  
1.75 
Latvia 9.33 3.43 0.45 0.91 0.89 1.73 9.72 0.54 9.04 5.09 33.12 20.37 1.04 
Denmark 15.02 9.30 0.03 2.26 0.52 33.31 1.82 0.04 3.46 0.35 18.05 7.18 0.26 
Slovenia 11.93 7.04 0.42 2.32 1.08 16.33 22.76 0.93 9.00 2.77 25.62 10.46 1.50 
Ireland 17.79 7.74 1.33 3.79 0.94 4.78 20.64 0.57 5.28 4.41 17.35 4.63 1.76 
Czechia 16.62 5.95 1.54 3.66 1.24 12.38 16.13 0.45 7.48 3.51 18.54 9.25 2.63 
Estonia 9.72 3.03 0.83 2.09 0.79 2.47 8.50 0.01 8.09 7.10 31.51 4.97 1.74 
Iceland 17.16 8.22 0.30 1.15 0.55 13.68 13.78 
 
3.22 1.24 14.05 5.96 0.63 
Finland 16.56 4.75 2.32 1.46 0.87 8.35 4.95 0.00 5.28 0.61 12.25 7.43 0.50 
Netherlands 10.11 3.24 0.04 1.48 0.89 3.83 11.99 0.08 8.63 5.03 18.20 3.05 1.61 
Lithuania 16.20 6.81 1.26 1.93 1.22 5.49 7.27 0.53 6.92 2.26 18.90 4.14 0.75 
UK 15.20 5.98 0.58 2.51 0.48 4.86 4.86 0.03 3.18 0.70 15.08 8.22 0.33 
Norway 14.89 6.25 0.13 1.68 0.51 24.49 0.01 0.03 3.41 0.19   0.19 
Sweden 13.69 6.61 0.24 0.76 0.79 28.41 1.16 0.19 5.75 0.15 11.87 1.70 0.21 
2009 quartile distribution 
 3.03 0.03 0.76 0.48 33.31 0.01 0.00 3.18 0.15 11.87 –3.61 0.19 
 5.14 0.64 1.91 0.89 8.08 8.81 0.04 6.38 2.96 18.12 4.80 1.16 
 6.92 1.89 2.97 1.29 4.30 16.79 0.71 8.76 5.75 26.26 8.22 2.07 





p100 34.60 10.91 8.67 11.56 4.10 0.01 32.38 8.66 15.90 126.74 56.78 32.40 17.42 
aCoverage in 2009 limited to 30%–40%. 
= values within the first quartile (i.e. p0 ≤ values ≤ p25) 
= values within the second quartile (i.e. p25 > values ≤ p50) 
= values within the third quartile (i.e. p50 > values ≤ p75) 
= values within the fourth quartile (i.e. p75 > values ≤ p100). 
Figure 2. Quality indicators for outpatient antibiotic consumption in the community, 2009 (ATC/DDD index 2019), 30 EU/EEA countries grouped into



































































Cyprus 28.88 9.33 5.81 2.89 6.21 0.23 25.01 3.57 21.49 38.07 8.85 
Italy 19.02 8.79 1.94 3.75 2.68 0.00 35.40 8.85 14.01 208.41 37.01 31.26 7.11 
Malta 19.79 7.34 3.12 4.46 2.18 0.70 34.04 2.93 11.02 61.25   23.36 
Romaniaa 24.50 11.22 4.95 2.89 3.25 2.58 26.44 5.19 13.23 15.73   3.45 
Greece 32.15 10.76 7.70 6.98 2.60 0.58 18.90 0.56 8.08 107.61 4.96 
Luxembourg 20.93 6.79 2.36 5.50 2.77 0.08 17.44 1.67 13.24 38.89 36.33 27.15 4.11 
Spainb 25.01 14.23 2.27 3.07 2.82 0.38 31.40 2.10 11.23 53.50 2.43 
Bulgaria 18.94 5.38 4.11 3.82 2.86 0.69 12.46 4.69 15.10 46.34 4.20 
Belgium 21.14 9.74 1.17 3.41 2.17 0.08 22.43 0.01 10.27 123.93 32.62 24.32 2.26 
France 22.97 13.00 1.60 3.04 1.37 0.73 19.65 5.37 5.96 37.97 1.22 
Hungary 13.43 4.51 2.10 2.80 2.40 0.97 26.98 2.28 17.89 62.28 51.31 46.67 12.28 
Portugal 16.37 8.67 1.64 2.44 1.26 0.08 37.16 1.50 7.67 39.19 27.62 15.81 3.96 
Poland 23.79 6.63 3.99 4.46 1.49 1.29 11.96 0.07 6.21 20.12 3.11 
Austria 11.92 5.12 1.51 2.81 1.23 6.27 29.74 2.01 10.32 6.90 59.15 48.03 4.56 
Germany 12.34 3.57 2.81 2.14 1.11 5.61 3.35 1.99 8.96 6.14 35.39 27.57 1.91 
Ireland 19.35 9.54 1.08 4.19 0.81 6.01 19.90 0.15 4.17 4.65 20.38 11.54 1.46 
Latvia 12.05 4.66 0.66 1.97 1.03 0.66 12.88 0.61 8.37 14.79 37.20 7.84 1.52 
Croatia 16.83 7.82 2.47 2.75 1.50 3.02 31.73 1.94 8.92 10.10 33.15 13.85 3.89 
Slovenia 10.74 6.87 0.37 1.68 1.11 14.62 26.88 0.52 10.30 3.04 29.86 8.97 1.49 
Iceland 18.84 9.34 0.61 1.61 0.81 9.99 16.16 0.03 4.30 1.67 13.66 1.69 0.74 
Denmark 14.33 9.52 0.03 1.62 0.44 26.61 5.51 0.04 3.08 0.61 10.56 5.11 0.32 
Estonia 9.94 3.47 1.18 2.26 0.79 1.67 17.13 0.03 7.90 14.70 30.56 9.06 2.97 
Lithuania 13.56 6.73 1.29 2.07 0.87 1.14 12.57 0.12 6.11 11.09 1.06 
Netherlands 8.94 2.92 0.03 1.38 0.73 2.45 10.59 0.05 8.19 8.60 1.50 
UK 17.06 6.37 0.24 2.90 0.45 5.02 4.09 0.06 2.65 1.74 11.07 4.54 0.53 
Finland 13.59 4.40 1.94 0.75 0.67 8.24 5.36 0.02 4.93 0.50 12.73 3.22 0.39 
Norway 14.37 5.61 0.06 1.01 0.35 20.89 0.09 0.04 2.46 0.16 0.15 
Sweden 11.26 5.87 0.08 0.54 0.63 28.02 1.78 0.02 5.59 0.20 0.22 
2009 quartile distribution 
 3.03 0.03 0.76 0.48 33.31 0.01 0.00 3.18 0.15 11.87 –3.61 0.19 
 5.14 0.64 1.91 0.89 8.08 8.81 0.04 6.38 2.96 18.12 4.80 1.16 
 6.92 1.89 2.97 1.29 4.30 16.79 0.71 8.76 5.75 26.26 8.22 2.07 





p100 34.60 10.91 8.67 11.56 4.10 0.01 32.38 8.66 15.90 126.74 56.78 32.40 17.42 
aCoverage in 2009 limited to 30%–40%. 
bPrivate prescriptions included since 2016. 
= values within the first quartile (i.e. p0 ≤ values ≤ p25) 
= values within the second quartile (i.e. p25 > values ≤ p50) 
= values within the third quartile (i.e. p50 > values ≤ p75) 
= values within the fourth quartile (i.e. p75 > values) 
Figure 3. Quality indicators for outpatient antibiotic consumption in the community, 2017 (ATC/DDD index 2019), 28 EU/EEA countries grouped into
four quartiles based on 2009 quartile distribution. For Cyprus and Romania, total care, i.e. community plus hospital sector, data were used.
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developed disease-specific quality indicators for antibiotic pre-
scribing in the community, i.e. antibiotic prescribing rates, pre-
scribing of recommended antibiotics and prescribing of
quinolones for seven main indications.23 National and even re-
gional quality assessments using these tools will help countries
and local practices to better understand prescribing habits and
identify opportunities for improvement.24–34 For example in
Belgium, such a quality assessment identified the unavailability
of narrow-spectrum penicillins (J01CE) in the country due to in-
dustry stock cuts,24 which calls for measures to make these
antibiotic substances accessible again.35
In conclusion, increased consumption of broad-spectrum
antibiotics in DDD per 1000 inhabitants per day and an increas-
ing seasonal variation were observed in EU/EEA countries
between 2009 and 2017. The quality of antibiotic consumption
further decreased between 2009 and 2017, especially in
Southern and Eastern European countries. Therefore, sustained
efforts to improve antibiotic consumption in the community are
essential to reduce antibiotic consumption in general and the
consumption of broad-spectrum antibiotics in particular.
The 2017 values of the ESAC DSQIs for antibiotic consumption in
the community and the ECDC/EFSA/EMA JSO indicator allow in-
dividual countries to assess their position in relation to other
countries, and we hope this will trigger actions to improve anti-
biotic consumption.
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